Triple Combinations of AAV9-Vectors Encoding Anti-HIV bNAbs Provide Long-Term In Vivo Expression of Human IgG Effectively Neutralizing Pseudoviruses from HIV-1 Global Panel
Viruses · 2024
DOI: 10.3390/v16081296 ↗Kurz gefasst
Fachartikel in der Zeitschrift Viruses, 2024. Verfasst von German A Shipulin und 8 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Strategic Planning and Management of Biomedical Health Risks, Federal Medical Biological Agency, 119992 Moscow, Russia. Hauptthemen laut MEDLINE: Dependovirus, HIV-1, HIV Antibodies, Antibodies, Neutralizing. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Anti-human immunodeficiency virus (HIV) broadly neutralizing antibodies (bNAbs) offer a promising approach for the treatment of HIV-1. The current paradigm for antibody therapy involves passive antibody transfer, requiring regular delivery of bNAbs in treating chronic diseases such as HIV-1. An alternative strategy is to use AAV-mediated gene transfer to enable in vivo production of desirable anti-HIV-1 antibodies. In this study, we investigated two sets of triple combinations of AAV9-vectors encoding different bNAbs: N6, 10E8, 10-1074 (CombiMab1), and VRC07-523, PGDM1400, 10-1074 (CombiMab2). We used CBAxC57Bl and C57BL/6 mouse models to characterize rAAV-induced antibody expression and to evaluate the neutralization capacity of mouse sera against a global panel of HIV-1 viral strains. rAAV9-mediated IgG expression varied between bNAb clones and mouse strains, with C57BL/6 mice exhibiting higher bNAb titers following rAAV delivery. Although CombiMab2 treatment elicited a higher IgG titer than CombiMab1, both combinations resulted in neutralization of all the viral strains from the global HIV-1 panel. Our data highlight the potential of AAV vectors as a long-term option for HIV-1 therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centre for Strategic Planning and Management of Biomedical Health Risks, Federal Medical Biological Agency, 119992 Moscow, Russia.
- Izmerov Research Institute of Occupational Health, 105275 Moscow, Russia.
ORCID-Profile: German A Shipulin, Felix A Urusov, Boris V Belugin, Valeriya Dontsova, Alyona A Borisova, Elena V Bogoslovskaya
Zitieren
APA
Shipulin, G. A., Glazkova, D. V., Urusov, F. A., Belugin, B. V., Dontsova, V., Panova, A. V., Borisova, A. A., Tsyganova, G. M., & Bogoslovskaya, E. V. (2024). Triple Combinations of AAV9-Vectors Encoding Anti-HIV bNAbs Provide Long-Term In Vivo Expression of Human IgG Effectively Neutralizing Pseudoviruses from HIV-1 Global Panel. Viruses. https://doi.org/10.3390/v16081296
Vancouver
Shipulin GA, Glazkova DV, Urusov FA, Belugin BV, Dontsova V, Panova AV, et al. Triple Combinations of AAV9-Vectors Encoding Anti-HIV bNAbs Provide Long-Term In Vivo Expression of Human IgG Effectively Neutralizing Pseudoviruses from HIV-1 Global Panel. Viruses. 2024. doi:10.3390/v16081296
BibTeX
@article{Shipulin2024,
author = {Shipulin, German A and Glazkova, Dina V and Urusov, Felix A and Belugin, Boris V and Dontsova, Valeriya and Panova, Alexandra V and Borisova, Alyona A and Tsyganova, Galina M and Bogoslovskaya, Elena V},
title = {Triple Combinations of AAV9-Vectors Encoding Anti-HIV bNAbs Provide Long-Term In Vivo Expression of Human IgG Effectively Neutralizing Pseudoviruses from HIV-1 Global Panel},
journal = {Viruses},
year = {2024},
doi = {10.3390/v16081296}
}
EUVIMED